Khan Muhammad Asim
Download Khan Muhammad Asim PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Khan Muhammad Asim book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages.
Ankylosing Spondylitis
Author: Muhammad Asim Khan
language: en
Publisher: Oxford University Press
Release Date: 2009-06-15
Ankylosing Spondylitis (AS) and related diseases called spondyloarthropathies (SpA) are the second most common form of chronic inflammatory arthritis after Rheumatoid Arthritis (RA). Unfortunately, most patients with AS and SpA are either never diagnosed, or they are inadequately treated. The current mean delay in the diagnosis of AS ranges from 5 to 10 years, and the presenting clinical manifestations of these diseases are wide-ranging and heterogeneous, and thus a variety of health care professionals see AS and SpA patients, from primary care physicians to rheumatologists and other medical and surgical specialists. With the availability of newer, highly effective treatments and better methods of musculoskeletal imaging, such as the MRI, there is an urgent need to improve early diagnosis and reduce any inappropriate delay in obtaining effective treatment. Earlier diagnosis and treatment can mitigate the severity of the disease, and make a meaningful difference for patient care and quality of life. The proposed book is designed for specialists and generalists alike, and is intenteded to expedite accurate diagnosis and initiation of appropriate treatment in order to alleviate unnecessary suffering. Part of the new Oxford American Rheumatology Library series, this pocket-sized book provides practical, evidence-based information for clinicians to aid diagnosis, treatment, and follow-up care for patients with AS and SpA. The book provides pointers to early diagnosis, prognosis, clinical manifestations, socioeconomic aspects, and disease management. It also provides comprehensive coverage of current treatment options, including the latest biologics, as well as non-drug therapies.
Cancer Targeting Therapies
This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students. Features Timely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processes Provides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industries Draws on the author's vast experience in the field of industrial hygiene and hazardous materials Presents a collection of unique situations in which industrial hygiene was implemented to resolve a variety of scenarios and did not interfere with quality issues Addresses current topics relating to industry evolution such as migration of therapies to higher potency, RiskMAP, new modalities in medicines and treatments, large molecule therapeutics and conjugates
Endocrine Disrupting Chemicals-induced Metabolic Disorders and Treatment Strategies
Author: Muhammad Sajid Hamid Akash
language: en
Publisher: Springer Nature
Release Date: 2020-08-04
This volume offers a detailed and comprehensive analysis of Endocrine Disrupting Chemicals (EDCs), covering their occurrence, exposure to humans and the mechanisms that lead to the parthogenesis of EDCs-induced metabolic disorders. The book is divided into three parts. Part I describes the physiology of the human endocrine system, with special emphasis on various types of metabolic disorders along with risk factors that are responsible for the development of these disorders. Part II addresses all aspects of EDCs, including their role in the induction of various risk factors that are responsible for the development of metabolic disorders. Part III covers up-to-date environmental regulatory considerations and treatment strategies that have been adopted to cure and prevent EDCs-induced metabolic disorders. This section will primarily appeal to clinicians investigating the causes and treatment of metabolic disorders. The text will also be of interest to students and researchers in the fields of Environmental Pharmacology and Toxicology, Environmental Pollution, Pharmaceutical Biochemistry, Biotechnology, and Drug Metabolism/Pharmacokinetics.